{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:31:23Z","timestamp":1791412283305,"version":"4.3.3"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jaad.2017.07.012","type":"journal-article","created":{"date-parts":[[2017,9,19]],"date-time":"2017-09-19T07:30:22Z","timestamp":1505806222000},"page":"1074-1082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab"],"prefix":"10.1016","volume":"77","author":[{"given":"Lauren N.","family":"Albers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Bo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Swerlick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron J.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jaad.2017.07.012_bib1","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1001\/jamadermatol.2013.6739","article-title":"Durable remission of pemphigus with a fixed-dose rituximab protocol","volume":"150","author":"Heelan","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2017.07.012_bib2","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.012_bib3","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1586\/eci.11.22","article-title":"Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses","volume":"7","author":"Feldman","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2017.07.012_bib4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2133.2011.10658.x","article-title":"Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy","volume":"166","author":"Feldman","year":"2012","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.07.012_bib5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000357031","article-title":"Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial","volume":"228","author":"Gregoriou","year":"2014","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.jaad.2017.07.012_bib6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2017.07.012_bib7","series-title":"Product Label for Rituxan (rituximab)","year":"2014"},{"issue":"1","key":"10.1016\/j.jaad.2017.07.012_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cei.12481","article-title":"Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: a prospective observational study","volume":"180","author":"Trouvin","year":"2015","journal-title":"Clin Exp Immunol"},{"issue":"175","key":"10.1016\/j.jaad.2017.07.012_bib9","doi-asserted-by":"crossref","first-page":"175ra30","DOI":"10.1126\/scitranslmed.3005166","article-title":"Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response","volume":"5","author":"Colliou","year":"2013","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.jaad.2017.07.012_bib10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/archdermatol.2009.9","article-title":"ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus","volume":"145","author":"Abasq","year":"2009","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2017.07.012_bib11","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jaad.2015.10.051","article-title":"Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission","volume":"71","author":"Daneshpazhooh","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2017.07.012_bib12","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2017.07.012_bib13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/jamadermatol.2013.8175","article-title":"Pemphigus disease activity measurements: pemphigus disease area index, autoimmune bullous skin disorder intensity score, and pemphigus vulgaris activity score","volume":"150","author":"Rahbar","year":"2014","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2017.07.012_bib14","unstructured":"Nickleach D, Liu Y, Shrewsberry A, et\u00a0al. SAS macros to conduct common biostatistical analyses and generate reports. Available at: http:\/\/analytics.ncsu.edu\/sesug\/2013\/PO-05.pdf. Accessed January 22, 2016."},{"key":"10.1016\/j.jaad.2017.07.012_bib15","series-title":"Survival Analysis Using SAS: A Practical Guide","author":"Allison","year":"2010"},{"key":"10.1016\/j.jaad.2017.07.012_bib16","unstructured":"Powell TM, Bagnell ME. Your \u201csurvival\u201d guide to using time-dependent covariates. SAS Global Forum 2012. Available at: http:\/\/support.sas.com\/resources\/papers\/proceedings12\/168-2012.pdf. Accessed January 22, 2016."},{"issue":"23","key":"10.1016\/j.jaad.2017.07.012_bib17","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","article-title":"Challenges of guarantee-time bias","volume":"31","author":"Giobbie-Hurder","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.012_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1198\/000313005X70371","article-title":"Illustrating the impact of a time-varying covariate with an extended Kaplan-Meier estimator","volume":"59","author":"Snapinn","year":"2005","journal-title":"Am Statistician"},{"key":"10.1016\/j.jaad.2017.07.012_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/biomet\/68.2.373","article-title":"On the regression analysis of multivariate failure time data","volume":"68","author":"Prentice","year":"1981","journal-title":"Biometrika"},{"issue":"11","key":"10.1016\/j.jaad.2017.07.012_bib20","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/1346-8138.12649","article-title":"Grading criteria for disease severity by pemphigus disease area index","volume":"41","author":"Shimizu","year":"2014","journal-title":"J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2017.07.012_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archderm.140.1.91","article-title":"Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody)","volume":"140","author":"Dupuy","year":"2004","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2017.07.012_bib22","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.jaad.2017.07.012_bib23","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/rheumatology\/ker526","article-title":"B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels","volume":"51","author":"Lazarus","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.jaad.2017.07.012_bib24","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1038\/jid.2008.172","article-title":"Rituximab exerts a dual effect in pemphigus vulgaris","volume":"128","author":"Eming","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2017.07.012_bib25","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/jid.2008.178","article-title":"B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses","volume":"128","author":"Mouquet","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2017.07.012_bib26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/978-1-62703-493-7_21","article-title":"Cylex ImmuKnow cell function assay","volume":"1034","author":"Zeevi","year":"2013","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.jaad.2017.07.012_bib27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00403-013-1355-4","article-title":"A prospective study on clinical response and cell-mediated immunity of pemphigus patients treated with rituximab","volume":"206","author":"Leshem","year":"2014","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"10.1016\/j.jaad.2017.07.012_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s13075-016-1152-5","article-title":"Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment","volume":"18","author":"Lavielle","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.jaad.2017.07.012_bib29","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1007\/s00296-015-3295-0","article-title":"Circulating CD4+ T-cell number decreases in rheumatoid patients with clinical response to rituximab","volume":"35","author":"Piantoni","year":"2015","journal-title":"Rheumatol Int"},{"issue":"4","key":"10.1016\/j.jaad.2017.07.012_bib30","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/art.38347","article-title":"Direct and indirect rituximab-induced T cell depletion: comment on the article by M\u00e9let et\u00a0al","volume":"66","author":"Eggleton","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.jaad.2017.07.012_bib31","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1159\/000099585","article-title":"CD4+CD25high regulatory T cells are markedly decreased in blood of patients with pemphigus vulgaris","volume":"214","author":"Sugiyama","year":"2007","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.jaad.2017.07.012_bib32","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1684\/ejd.2013.2177","article-title":"The imbalance of Th17 and regulatory T cells in pemphigus patients","volume":"23","author":"Xu","year":"2013","journal-title":"Eur J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2017.07.012_bib33","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/01.cco.0000172824.78318.b9","article-title":"Rituximab for HIV-associated lymphoma: weighing the benefits and risks","volume":"17","author":"Spina","year":"2005","journal-title":"Curr Opin Oncol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221732114X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096221732114X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:44:52Z","timestamp":1759272292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096221732114X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S019096221732114X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2017.07.012","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2017.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}